Apmonia Therapeutics

Is developing a portfolio of first-in-class peptides targeting the tumour microenvironment. Its most advanced programme, AP-01, is a cyclic peptide inhibiting TSP-1, a ligand of the CD47 receptor, in various tumour indications with a high medical need. Other promising programmes targeting the extracellular matrix are also in development.